JB Pharma, owned by the investment firm KKR & Co., aims to increase its revenue by 12-14% over the next few years, focusing on its domestic operations and its contract development and manufacturing organization (CDMO) segment. The company is also expanding into new markets, such as Europe and Brazil, through partnerships and product launches. CDMOs provide a variety of services to pharmaceutical companies, including drug development, manufacturing, packaging, and distribution.
JB Pharma is set to enter new regions with new product offerings. Since the start of the fourth quarter of fiscal year 2024, the company has introduced lozenges – an oral drug form that enhances bioavailability, which is a key part of its CDMO business – in four European countries, with plans to expand across Europe by the second half of the next fiscal year.
JB Pharma is collaborating with leading global companies like Reckitt, P&G, J&J, and Inova to produce cough and cold lozenges. As reported by mint, the company is also looking to diversify its product range to include lozenges for sleep disorders, anti-inflammatory lozenges, and immunity-boosting lozenges.
